12:49 PM
 | 
May 26, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AbbVie starts Phase I for TRAIL-receptor agonist in cancer

Apogenix AG (Heidelberg, Germany) said partner AbbVie Inc. (NYSE:ABBV) began a Phase I trial to evaluate ABBV-621 (APG880) in 92 patients with relapsed or refractory solid tumors, non-Hodgkin’s lymphoma (NHL) or acute myelogenous leukemia (AML).

The first part of the open-label, international trial will test...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >